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ABSTRACT
DIFFERENTIAL MIGRATION OF CD4+ AND CD8+ T CELLS DURING AN IMMUNE RESPONSE
by
Jacob Parrott
The University of Wisconsin-Milwaukee, 2018
Under the Supervision of Professor Douglas Steeber

Lymphocyte migration is critical for recognizing pathogenic challenges in a timely manner and
generating effective, rapid immune responses. Lymphocyte numbers in secondary lymphoid
tissues such as lymph nodes are rapidly and dramatically increased during an immune response.
Lymphocytes use specific adhesion molecules and intracellular signaling cascades to migrate
and enter secondary lymphoid tissues under resting conditions. It is not clear if the same
migration and/or entry pathways are utilized when secondary lymphoid tissues are activated
during an immune response. Previous investigations in our lab have shown that T cell subtypes
display differential migration patterns to peripheral lymph nodes during an antigen-induced
immune response. Additional studies began defining the intracellular signaling cascades and
adhesion molecules that may be responsible for the observed differential migration. In the
studies presented here, inhibitors of proteins in signaling pathway(s) known to be involved in
lymphocyte adhesion and migration were used to identify the intracellular signaling cascades
responsible for the observed differential migration. Further, examination of cryosectioned
lymphoid tissue by immunofluorescence microscopy sought to elucidate involvement of the
inhibited pathways in cellular localization in vivo and the expression of peripheral lymph node
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addressin in the recruitment of T cells to peripheral lymph nodes. Several possible intracellular
signaling pathways (PI3K and ZAP70) and L-selectin (CD62L) were eliminated as the cause of the
differential T cell migration during immune responses.
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Significance
Immunotherapy has garnered much interest in the therapeutic world recently.
Immunotherapy, as defined by the National Cancer Institute, is a type of biological therapy that
uses substances to stimulate or suppress the immune system to help the body fight cancer,
infections, and other diseases. Examples of immunotherapy treatments include monoclonal
antibodies (alemtuzumab, (Campath®), Nivolumab (Opdivo®)), cancer vaccines (Sipuleucel-T
(Provenge®)), cytokine administration, and chimeric antigen receptor T cell (CAR-T cell)
transfers. The majority of FDA approved immunotherapies are monoclonal antibody treatments
for cancer therapies. However, the other areas of immunotherapy have a large amount of
research interest. Specifically, CAR-T cell treatments have been of much interest lately as
evidenced by the $605 million in venture capital given to companies developing CAR-T cell
therapies from 2011-16 (Smith et al., 2016).
CAR-T cell treatments involve ex vivo expansion and/or genetic modification of tumorspecific T cells and then adoptive transfer of the cells back into the patient. This has shown
some promising results (Morgan et al., 2006, Milone et al., 2009). However, the first generation
of chimeric T cell therapies displayed limited efficacy in clinical trials and had issues with
toxicity due to self-targeting cells (Kershaw et al., 2006, Lamers et al., 2006). The moderate
efficacy has been tied to limited migration of the engineered cells (Kersahaw et al., 2006).
Immunosuppressive factors, such as inhibition by indoleamine-2,3-dioxygenase, programmed
cell death ligand-1, and regulatory T cells have also been suggested to play a part in reducing
the efficacy of CAR-T cell treatments (Bellone and Calcinotto, 2013).
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Understanding the mechanisms underlying T cell migration could help direct the CAR T
cells to the desired location (tumor site in this case). Indeed, there is interest in this avenue of
investigation at the preclinical stage (Dai et al., 2016). This control may not be restricted to
controlling T cell migration in response to cancer. Understanding T cell migration could be
useful for any type of illness or disease where a directed immune response is desired.
Characterizing the mechanism for previously observed differential T cell subset migration would
be a step in this direction (Grailer et al., 2010).
Related to CAR-T cell therapies, cancer vaccines seek to increase the immune system’s
anti-tumor immune response. Indeed, tumor-infiltrating lymphocytes are a good prognostic
factor when predicting patient outcomes in diverse cancer types (Hwang et al., 2012). The most
common approach is to present the patients’ immune cells with tumor associated antigens (e.g.
MART-1, gp100) or autologous tumor cells (Butterfield, 2015). Activation of CD8+ T cells is the
most common outcome sought using these methods. Vaccines that include antigen presenting
cells, MHC class 1 restricted tumor-associated antigen peptides, tumor cells reengineered to
express stimulatory cytokines, and oncolytic viruses are ways that have been used to activate
patient-derived CD8+ T cells (Butterfield, 2015).
This antigen presentation approach has been applied to autoimmune diseases in
antigen-specific immunotherapy (ASI) regimens as well. The goal of ASI, like cancer vaccines, is
to reprogram or otherwise reroute cells reacting to self-antigens (Pozsgay et al., 2017).
Although these ideas have generated a lot of research interest, clinical trials have only shown
moderate responses (Butterfield, 2015; Butterfield, 2013). Many have sought to increase the
efficacy of the vaccine immunotherapies, with some promising results (Diaz et al., 2013;
2

Bluestone et al., 2015). Knowing how to manipulate the migration of immune cells to, or away
from, disease affected area(s) could help create more efficacious immunotherapies.

Rationale
Grailer et al., in our lab, examined the subset recruitment of T and B cells based on
much earlier observations (Mackay et al., 1988; Abernathy et al., 1990; Kimpton et al., 1989).
These studies showed subset-specific differences in the migration of CD4+ and CD8+ T cells, and
B cells. Previous work in our lab also found differences in lymphocyte subset migration during
an immune response (Figure 1). Specifically, CD4+ T cell migration to the peripheral lymph
nodes (PLN) peaked earlier following immunization (Day 3) than CD8+ T cell migration (Day 7;
Figure 1). Attempts were made to tease apart the mechanism(s) regulating differential
migration during an immune response, including examining adhesion molecules and
intracellular signaling pathways known to be involved in leukocyte migration. Specifically, these
studies examined the role of lymph node neovascularization, L-selectin (CD62L) function,
peripheral lymph node addressin (PNAd) expression, and Gi-dependent chemotaxis. The use
of vascular endothelial growth factor 2 receptor (VEGFR2) inhibitor SU5416 showed that
neovascularization did not account for the observed differential migration. L-selectin expression
was found to be necessary for mediating increased migration to the immunized PLN by
adoptive transfer of L-selectin-/- lymphocytes into wild type mice. Interestingly, based on
immunofluorescence microscopy data, PNAd expression did not increase on the vasculature of
the PLN as a result of immunization. Surprisingly, despite blocking the majority of lymphocyte
migration into the PLN, inhibiting Gi signaling in lymphocytes with pertussis toxin (PTX) did not
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prevent increased migration occurring into the immunized PLN (Figure 2). These findings leave
the mechanism(s) mediating the observed differential migration unclear. A better
understanding of this process could help improve the current forms of immunotherapy.

Figure 1. Immunization significantly increases the percent of injected CD4+ and CD8+ T cells that
migrate to PLN. C57BL/6 splenocytes were biotinylated and injected into the lateral tail vein and
allowed to migrate for 1 hour in immunized mice (days 1 thru 7). PLN were harvested, injected cells
were labeled with avidin-conjugated fluorophores and subset-specific antibodies then analyzed by flow
cytometry. C = unimmunized control values. *; P<0.05. Reproduced from Grailer 2010.

Figure 2. Inhibition of Gαi with pertussis toxin (PTX) had no effect on increased recruitment of T cells
following immunization. Cells were incubated with PTX (10 µM) for 1 hour before adoptive transfer into
4

recipient mice that had been immunized 3 days earlier. Migration was allowed to occur for 1 hour
before PLN were harvested and analyzed as in Figure 1. †; P<0.05. Reproduced from Grailer 2010.

The aims and hypothesis detailed in the next section were investigated to uncover the
mechanism(s) causing differential migration between CD4+ and CD8+ T cells to secondary
lymphoid organs during an immune response.

5

Aims and Hypothesis
Hypothesis
Differences in migration between CD4+ and CD8+ T cells to secondary lymphoid tissues during
an immune response are caused by differences in signaling pathway activation and not changes
in adhesion molecules.
This hypothesis was tested through the following aims:
1. Determine the role of kinase signaling in mediating differential CD4 +/CD8+ T cell
migration following antigen stimulation. Migration following treatment of T cells
with inhibitors against key signaling proteins including ZAP70 and
phosphatidylinositol 3-kinase (PI3K) was analyzed using flow cytometry and
immunofluorescence microscopy.
2. Determine the role of known adhesion molecules (i.e., L-selectin, L-selectin
ligands) in mediating differential CD4+/CD8+ T cell migration following antigen
stimulation using chimeric L-selectin fusion protein binding.

6

Literature Review
Lymphocytes must recirculate in the blood and/or migrate throughout the body for an
efficient immune response to occur. Recirculation and migration are critical for a proper
immune response because the odds of a lymphocyte recognizing a given antigen are low. For
example, the odds of a naive CD8+ T cell being specific for an 8 amino acid epitope on the
lymphocytic choriomeningitis virus was estimated to be 1 in 200,000 (Blattman et al., 2002).
Continual movement of lymphocytes through the lymphoid system via recirculation and
migration must be in place to ensure that a specific lymphocyte will encounter its specific
antigen. The inability to properly migrate and/or recirculate can lead to the inability of a patient
to defend his or herself against immune challenges. Leukocyte adhesion deficiency (LAD) is an
example of such a disorder (Harris et al., 2013). Patients with LAD are unable to clear bacterial
infections, and usually succumb to the disease at a young age if no treatment is received (Tipu,
2017). An important part of this defense is the transition from the circulation in the blood to
migration into the lymph nodes. Lymphocytes achieve this transition by undertaking the
adhesion pathway.
The adhesion pathway for transendothelial migration has been well defined (Ley et al.,
2007). There are four overlapping steps in the pathway. Transitory L-selectin binding to PNAd is
the first step. This transitory binding allows the L-selectin+ cells to roll along the cell membranes
of PNAd expressing endothelial cells. Secondly, integrins on the rolling cells are activated by
chemokines decorated on the cell membranes of the PNAd+ cells. The integrins go from an
inactive state to an active state when the appropriate chemokine(s) are bound. In the third
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step, the active integrins then bind to their appropriate ligand, primarily intercellular adhesion
molecule-1 (ICAM-1) in the peripheral lymph nodes, and stop the cell in what is called firm
adhesion. Finally, cells undergo transendothelial migration (also called extravasation or
diapedesis), exiting the blood stream and entering the tissue. The chemokines that activate the
integrins can vary depending on the tissue and immune status. During homeostasis, the
chemokines CCL19 and CCL21 are the dominant chemokines causing integrin activation. There
are several other chemokines that are thought to be important in the direction of immune cells
to lymphoid organs and/or sites of inflammation (Luster et al., 2005).
L-selectin’s role in the adhesion cascade should be emphasized. Indeed, without Lselectin expression there is a 70-90% reduction in extravasation into lymph nodes by
lymphocytes (Steeber et al., 1996). L-, P-, and E-selectin make up the selectin family. L-selectin
is expressed on all leukocytes, E-selectin is expressed on inflamed endothelial cells (along with
some P-selectin), and P-selectin is expressed on activated platelets (Grailer et al., 2009). The
selectins are characterized by a calcium-dependent lectin domain, an epidermal growth factorlike domain, and short consensus repeat domains (Grailer et al., 2009). L-selectin recognizes the
6-sulfo sialyl Lewis x (sLex) domain that is expressed in PNAd to mediate its binding (Rosen,
2004). It is of note that the sLex domain is usually identified by the MECA-79 antibody (Rosen,
2004).
Finally, as it pertains to this work, L-selectin contains a membrane proximal cleavage site
that is not found in the other selectins (Chen et al., 1995; Grailer et al., 2009). Cleavage of Lselectin is a necessary process for cells to maintain an appropriate amount of surface-bound L-
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selectin. Blocking L-selectin cleavage results in an increase in L-selectin expression levels that
alter the normal migration patterns of leukocytes (Venturi et al., 2003).
Chemokines, shortened from chemotactic cytokines, are proteins used to control the
migration of immune cells (Griffith et al., 2014). Chemokines are 8-12kDa proteins that are
categorized by the position of conserved N-terminus cysteine residues (Turner et al., 2014). The
four major subfamilies of chemokines are CC, CXC, C, and CX3C that bind to their respective
receptors (e.g., CCR, CXCR) (Turner et al., 2014). The chemokines that are most important in
lymphocyte migration, and therefore most commonly studied, are the CC and CXC chemokines.
Indeed, CCL21 is an example of a chemokine important for regulating homeostatic lymphocyte
migration into lymphoid tissues. Further, CCR7, and its ligands CCL21/19, regulate the majority
of naïve T cell migration. CXCR4 and CXCL12 is another receptor-ligand pair that directs
migration of naive T cells, albeit to a lesser extent than the CCR7-CCL19/21 paring (Scimone et
al., 2004). These chemokines, along with the adhesion pathway described above, allow
lymphocytes to recirculate from the blood to a secondary lymphoid organ and then back to the
blood every 10 to 20 hours (Mandl et al., 2012).
G proteins are heterotrimeric guanine nucleotide binding regulatory proteins that are
responsible for relaying intracellular signals from G-protein coupled receptors (GPCRs) on the
cell membrane (Syrovatkina et al., 2016). They have been extensively studied and the majority
of the signaling pathways utilized by GPCRs have been elucidated. GPCRs are of particular
interest in immunology because of their importance regulating migration of leukocytes (Griffith
et al., 2014). CCR7, described above, is an example of a GPCR. The G proteins responsible for
the intracellular signaling activity of GPCR are composed of andsubunits (Syrovatkina et
9

al., 2016). The subunit is known to dissociate from the GPCR as an individual subunit, but the
andsubunits are tightly associated. These two subunits are considered as one unit when
examining the signaling pathways used by GPCRs. G proteins can be divided into four families
based on the sequence similarity of the subunit. The families are Gs, Gi, Gq, and G12
(Syrovatkina et al., 2016). The Gifamily is the most diverse family of G proteins and are the
most relevant for signaling in leukocytes (Griffith et al., 2014, Syrovatkina et al., 2016).
The receptor part of the GPCR consists of seven-transmembrane helices. These
receptors, in conjunction with the associated G proteins, transmit the signal from outside to
inside the cell following chemokine binding. Interestingly, CD4+ and CD8+ T cells have different
transit times through lymph nodes (Mandl et al, 2012). Mandl et al., investigated the cell
surface molecules that could account for the transit time difference, and found that CCR7 was
about two-fold higher expressed on CD4+ T cells compared to CD8+ T cells. However, they were
not able to conclude that the increase in CCR7 expression accounted for the transit time
difference.
The GPCR subunit has been shown to interact with phosphoinositide 3-kinase (PI3K)
to mediate leukocyte migration in response to chemokines (among other chemoattractants)
(Ward et al., 2011). Indeed, the PI3K p100subunit has been shown to be necessary for
migratory responses to antigen (Jarmin et al., 2008). Interestingly, there seems to be a
preference for different catalytic subunits of PI3K based on the signal a lymphocyte receives
(Thomas et al., 2008). PI3K has several functions in the cell, but the most relevant for
lymphocyte migration is its role in actin dynamics (Sinclair et al., 2008, Martin et al., 2008,
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Nombela-Arrieta et al., 2007). Further, the p100subunit of PI3K controls CD62L expression
through mitogen activated protein kinases (MAPKs) and the mammalian target of rapamycin
(mTOR) pathway (Sinclair et al., 2008). The PI3K pathway connects with the mTOR pathway to
mediate lymphocyte differentiation and migration (Powell et al., 2012). Signals that enter the
mTOR pathway can travel through mTOR Complex 1 (mTORC1) or mTOR Complex 2 (mTORC2)
(Pollizzi and Powell, 2015). Signaling through PI3K and mTOR has also been found to be at a
crossroads between T cell metabolism and migration (Sinclair et al., 2008).
Hypoxia-inducible factor 1 (HIF-1) has also been shown to be required for proper CD8+ T
cell immune response and is dependent on mTORC1 function (Finlay et al., 2012). Specifically,
HIF-1 knockout results in CD8+ T cells maintaining CCR7, among other chemokine receptors, and
L-selectin expression following activation (Finlay et al., 2012). This finding was the result of
dysregulated glucose uptake by the HIF-1 knockout cells. The maintained expression of these
molecules was recapitulated by activating CD8+ T cells in a low glucose environment (Finlay et
al., 2012). These results implicate metabolism, and glucose availability, as important regulators
of changes in migration patterns of CD8+ T cells during an immune response.
Rapamycin inhibition of mTOR also results in CD8+ T cells maintaining high levels of CCR7
and CD62L expression after activation (Sinclair et al., 2008). Activated CD8+ T cells usually have
low expression of CCR7 and CD62L so that they break out of homeostatic recirculation
pathways. These activated cells then search for inflammatory sites to perform their cytotoxic
effector functions. Indeed, rapamycin treatment of IL-2-stimulated CD8+ T cells caused an
increase in the number of CD8+ T cells found in the lymph nodes and spleen (Sinclair et al.,
2008). 3-phosphoinositide-dependent kinase 1 (PDK1) is a kinase that binds phosphoinositide
11

(3,4,5)-triphosphate (PIP3) that can be released during cell activation (Waugh et al., 2009).
PDK1 is necessary to then signal downstream to regulate trafficking of CD8+ T cells, in the same
way as PI3K regulation of the mTOR pathway, during homeostasis and inflammatory responses
(Waugh et al., 2009).
ZAP70 is an intracellular protein kinase that binds to the cytoplasmic domain of the T
cell receptor (TCR) and is phosphorylated when the TCR is engaged by an appropriate major
histocompatibility complex (MHC) molecule loaded with peptide (Chan et al., 1992). ZAP70 is
necessary for proper immune function, and one form of severe combined immunodeficiency
results when ZAP70 is non-functional (Chan et al., 1994). ZAP70 function has also been
implicated in T cell migration (Lin et al., 2010). Specifically, Lin et al., showed that inhibiting
ZAP70 affected the directionality of T cell movement in vitro. They also showed that ZAP70
interacted with integrin talin domains but could not show that ZAP70 phosphorylated these
domains. Talin domains associate with cytoplasmic portions of integrins after they are activated
by GPCR signaling (Critchley, 2004). This association allows the proper activation of integrins
(Boettner and Van Aelst, 2009). Indeed, lack of adhesion is observed when talin is not present
in cells (Priddle et al., 1998). These results correlate ZAP70 function and integrin activation
which, as has been discussed above, is a critical step for migration of T cells. Part of the present
work was to investigate the role of ZAP70 during in vivo migration of T cells during an immune
response.
Wortmannin is a metabolite of the plant pathogen Penicillium funiculosum that has
been used since the early 1990’s as a non-selective covalent inhibitor of PI3Ks (Yano et al.,
1993). The metabolite has been shown to be a more potent inhibitor of PI3Ks than the first
12

synthetic PI3K inhibitor LY294002 (2-4 nM versus 0.5-1 μM respectively). Both of these
inhibitors, as well as other ‘first generation’ analogues, were examined in clinical trials after
PI3K signaling was implicated in cancer (Westin et al., 2014). However, these first generation
PI3K inhibitors were not very successful in trials as intolerable off-target effects and/or
solubility issues were uncovered (Yap et al., 2008). Both inhibitors have continued to be widely
used for basic research nevertheless (especially where specificity is not required). Further,
wortmannin has been used by many groups to study the role of PI3K signaling in immune cell
migration (Dey et al., 2010, Wain et al., 2002, Reif et al., 2004).
Piceatannol, the other inhibitor used in the present work, is an analogue of revesterol,
formed by addition of a hydroxyl group by cytochrome P450 during metabolism, that retains
revesterol’s antiproliferative and antioxidant effects (Murias et al., 2005, Wolter et al., 2002).
Piceatannol has also been shown to inhibit ZAP70 signaling (Soede et al., 1998). This inhibition
has been shown to reduce effector protein secretion and expression in vitro (Kim et al., 2015).
Piceatannol inhibition of ZAP70 has also been shown to interfere with the directionality of T cell
migration to cancer spheroids in a 3-D culture system (Lin et al., 2010). Further, previous
studies in the Steeber lab described a role for ZAP70 in migration of T cells out of the high
endothelial venules (HEV) and into the PLN (Subramanian et al, 2012).
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Experimental Methods
Mice
C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME) were housed and bred in
pathogen-free, climate-controlled conditions according to the Institutional Animal Care and Use
Committee at the University of Wisconsin-Milwaukee. Both male and female mice aged
between 8 and 12 weeks old were used.
Immunization
Alum-precipitated mariculture Keyhole Limpet Hemocyanin (mcKLH) (Pierce, Waltham,
MA) was used to create a robust immune response in the mice. The mcKLH (10 mg/mL stock
concentration) and alum (Pierce, Waltham, MA) was combined in a 1:1 ratio and mixed with a
magnetic stir rod for 30 minutes at room temperature prior to use. 125 µg of the mcKLH-alum
in 25 µL volume was injected into the hind and fore footpads on one side of the recipient mice.
25 µL of PBS (0.15 M NaCl, 155 mM Na2HPO4, 46.6 µM Na2H2PO4 monohydrate) was injected
into the opposite hind and fore footpads of the mice as a control for injection. The immune
response was allowed to progress for 3 to 7 days. Cells prepared as described below were
adoptively transferred into the immunized mice by lateral tail vein injection.
Adoptive Transfer Assay
Donor spleens from C57BL/6 mice were dissociated using 27 gauge needles and
splenocytes were collected after being filtered through a 70 µm nylon mesh. Erythrocytes were
lysed with a 0.15 M ammonium chloride solution. Cells were counted with a hemacytometer
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and then 25x106 cells/mL were labeled with EZ-Link Sulfo-NHS-LC-Biotin (Thermo Scientific,
Waltham, MA) at a final concentration of 80 µg/mL. Alternatively, 12x106 cells/mL were labeled
with carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen, Carlsbad, CA) at a final
concentration of 0.5 µM. CFSE labeled or biotinylated cells were incubated with pertussis toxin
at 100 ng/mL (List Biological Laboratories, Campbell, CA), piceatannol at 10 µM (Enzo Life
Sciences, Farmingdale, NY), or wortmannin at 100 nM (Upstate Cell Signaling, Lake Placid, NY)
for 1-hour inhibitor transfer assays. Labeled cells were washed 3 times in PBS and injected i.v.
through the lateral tail vein of recipient mice. Cells were allowed to migrate for 5 minutes or 1
hour before the animal was euthanized. Spleen and popliteal and axillary lymph nodes were
dissected from the recipient mice. The popliteal and axillary lymph nodes were combined, and
single-cell preparations were made from all tissues as described above for the donor cells.
Lymph nodes, spleen, and pre-injection cells were labeled with avidin-PE (SouthernBiotech,
Birmingham, AL), anti-CD4 Alexa Fluor® 647, anti-CD8 Alexa Fluor® 647 (both BD Bioscience,
San Jose, CA), or isotype control antibodies (SouthernBiotech). Anti-CD4 Alexa Fluor® 647 was
used at 1:1000 dilution and anti-CD8 Alexa Fluor® 647 was used at 1:250. Cells with the light
scattering properties of mononuclear cells were gated, and 500-2000 adoptively transferred
and labeled cells were collected per sample using a FACSCalibur flow cytometer (BD
Biosciences, San Jose, CA). The percent of injected cells was calculated by dividing the number
of labeled subtype cells (CD4+ or CD8+ T cells) found in a tissue (e.g. spleen or PLN) by the
corresponding number of subtype cells injected. Ro/Ri was calculated by dividing the ratio of
inhibitor vs. control treated cells recovered (Ro) by the ratio of inhibitor vs. control treated cells
injected (Ri) ((inhibitor vs. control cells recovered) / (inhibitor vs. control cells injected)).
15

Immunofluorescence Microscopy
Tissues were harvested from donor mice, placed in a base mold containing Optimal
Cutting Temperature (OCT) tissue freezing medium (Sakura FineTek, Torrance, CA) and frozen
on dry ice. Tissues were then stored at -20°C until use. Tissues were sectioned with a Leica
CM1900 cryostat and collected on Superfrost Plus® microscope slides (VWR International, West
Chester, PA). Sections were stored at -20°C until use. Slides were allowed to warm to room
temperature, fixed in cold (-20°C) acetone, and allowed to air dry. Sections were encircled using
a hydrophobic pen (PAP pen; Biotium, Freemont, CA) before being rehydrated with PBS
containing 2% (v/v) horse serum (wash buffer) and blocked with 2% normal goat serum in PBS.
Tissues were then labeled with anti-CD4 or anti-CD8 Alexa Fluor® 647-conjugated antibodies,
MECA-79 culture supernatant (American Type Culture Collection, Manassas, VA), or isotype
control antibodies, as specified, in the dark. MECA-79 labeling was detected using DyLight 405conjugated AffiniPure goat-anti-rat IgM antibody (Jackson Immuno Research, West Grove, PA).
Biotin+ cells were revealed by using avidin conjugated with TRITC (Jackson Immuno Research,
West Grove, PA). Sections were washed with wash buffer at room temperature between
staining steps, and with PBS at room temperature after all staining steps were completed.
Finally, slides were mounted under glass coverslips with ProLong™ Gold antifade mountant
(Invitrogen, Eugene, Oregon) and imaged using a Nikon Eclipse TE-2000U inverted fluorescence
microscope (Nikon, Melville, New York). Images were captured with a CoolSNAP ES camera
(Photometrics, Tucson, Arizona) and analyzed using MetaVue software (Molecular Devices,
Sunnyvale, California). Cells per 1000 μm2 HEV was calculated by adding all of the biotin+ cells
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counted in the HEV field and then dividing by the total μm2 of HEV found in that field. Total μm2
of HEV was calculated using the measure tool in MetaVue.
Statistics
Data are presented as the mean ± SEM unless stated otherwise. Significant differences
between sample means was determined by Student’s t test. A p value of <0.05 was considered
statistically significant.
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Results
Mice were immunized with mcKLH-alum in the hind and fore footpads on one side and
PBS on the contralateral side and allowed to respond for 3 or 7 days. Figure 3 shows that the
immunization protocol described significantly increased the cellularity of the stimulated PLN
compared to the contralateral control tissues by day 3. Additional increase in cellularity of the
immunized lymph nodes was observed at day 7 (data not shown). These data further show that
the immunization protocol elicited an immune response only on the immunized side of the
animal. Therefore, this protocol was used to examine differences in lymphocyte migration for
all future lymphocyte transfer assays.

Number of Cells (1x106)

20

***

16
12
8

4
0

Control

Immunized
PLN Treatment

Figure 3. Immunized PLN have significantly increased cellularity compared to control PLN. Mice were
immunized with mcKLH-alum in the hind and fore paw on one side and PBS on the contralateral side.
Mice were allowed to respond for 3 days before PLN were removed. Values represent the mean ± SEM
total cell counts from at least 4 independent experiments. ***, P<0.001
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Figure 4 shows flow cytometry data from a control experiment where biotinylated and
CFSE-labeled cells were untreated, mixed together and allowed to migrate for 1 hour in a
recipient mouse. The left panel in Figure 4A shows a representative example of how
biotinylated CD4+ T cells were gated (R2) while gating of CFSE-labeled CD4+ T cells (R3) is shown
in the right panel. CD8+ T cells were analyzed similarly (data not shown). Figure 4 shows that
labeling with CFSE or biotin does not affect migration of CD4 + or CD8+ T cells relative to one
another as indicated by a Ro/Ri ratio of 1. Further, flow cytometry analysis showed that CCR7
and CD62L expression were not significantly changed at the time the cells were injected due to
cell handling and/or labeling (data not shown).
Pertussis toxin (PTX) is known to inhibit the Gi subunit of the GPCR, and therefore
inhibits Gidependent migration. Specifically, lymphocyte responses to CCL21/19 (as detailed
above) are dependent on Gisignaling. Figure 5 shows that treatment with PTX virtually
eliminated migration to PLN for both CD4+ and CD8+ T cells in 1 hour adoptive transfer
experiments. This serves as a positive control for other inhibitor transfer assays and indicates
that this assay can detect differences in migration for both CD4+ and CD8+ T cells.
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Figure 4. Biotin and CFSE labeling procedures do not affect the migratory ability of T cells. Equal
numbers of biotin- and CFSE-labeled cells (36x106 total cells) were injected into the lateral tail vein of a
C57BL/6 mouse immunized three days prior and allowed to migrate for 1 hour. A) Left panel: BiotinAvidin-PE-labeled CD4+ T cells are contained in the R2 gate; Right panel: CFSE-labeled CD4+ T cells are
contained in the R3 gate. The vertical dashed line in each panel indicates transferred biotin+ or CFSE+
cells that were recovered. B) The ratio of CFSE- to biotin-labeled cells recovered in the organ (Ro) was
divided by the ratio of CFSE- to biotin-labeled cells injected (Ri) to normalize migration results as
described in the methods section. The horizontal dashed line indicates equal migration of biotin- and
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CFSE-labeled cells (Ro/Ri = 1). A value over 1 indicates increased migration of the CFSE-labeled cells, and
a value under 1 indicates decreased migration. In this example both groups of cells were untreated and
thus a result near 1 is expected. Results are from 1 experiment.

A

Spleen

CD4-Alexa Fluor 647

PTX

R2

R3

R2

R3

CD4-Alexa Fluor 647

Immunized PLN

Control

CFSE

Biotin-Av-PE

B

CD4

CD8

1.2
1.0
Ro/Ri

0.8
0.6
0.4
0.2
0.0
Immunized PLN

Control PLN
Tissue

Spleen

Figure 5. PTX treatment reduces the migration of T cells to PLN. Cells were labeled with either biotin or
CFSE. CFSE-labeled cells were treated with PTX (100ng/mL) for 1 hour and then mixed with an equal
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number of vehicle-treated (control) biotin-labeled cells. Combined cells were injected into the lateral tail
vein of day 3 immunized recipient mice and allowed to migrate for 1 hour. A) Top Left: Control-treated
CD4+ T cells (R2) in the immunized PLN; Top Right: Pertussis toxin (PTX)-treated CD4+ T cells (R3) in the
immunized PLN; Bottom Left: Control-treated CD4+ T cells in the spleen; Bottom Right: PTX-treated
labeled CD4+ T cells in the spleen. B) Recovered cells were compared by the Ro/Ri ratio as above. Results
are from 1 experiment.
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CD8

Figure 6. Piceatannol treatment did not significantly affect T cell migration to the PLN. Piceatannol
(10µM) was incubated with splenocytes for 1 hour before being adoptively transferred to recipient mice
that had been immunized 3 days (A) or 7 days (B) prior and allowed to migrate for 1 hour. Recovered
cells were compared by the Ro/Ri ratio as above. Bars represent the mean ± SEM of results from 3
independent experiments. * significantly different from control-treated cells; † significantly different
from CD4+ T cells; p<0.05.

Adoptive transfer assays using piceatannol-treated cells to inhibit ZAP70 function were
performed and analyzed in the same way as the control and PTX treatment experiments
described above. Recipient mice were immunized 3 or 7 days before adoptive transfer of
piceatannol- or vehicle-treated control cells. Figure 6 shows that piceatannol treatment did not
have a significant effect on 1 hour CD4+ or CD8+ T cell migration to control or immunized PLN.
However, CD8+ but not CD4+ T cell migration was significantly reduced to the spleen for both
day 3 and 7 transfers. This suggests that signaling through ZAP70 is dispensable for migration to
PLNs during an immune response.
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Figure 7. Wortmannin treatment did not significantly affect T cell migration to the PLN. A) Splenocytes
were prepared, treated with 10nM Wortmannin (A), or 100nM Wortmannin (B) and adoptively
transferred into recipient mice that had been immunized 3 days prior. Bars represent the mean ± SEM of
results from 3 independent experiments. * significantly different from control-treated cells; p < 0.05.

Additional adoptive transfer experiments were performed treating cells with
wortmannin (10 or 100 nM) to inhibit PI3K activity. Similar to treatment with piceatannol
treatment, neither concentration of wortmannin significantly reduced migration to control or
immunized PLN after 1 hour of migration (Figure 7A-B). While a slight reduction in CD8+ T cell
migration to the spleen was found with the 10 nM wortmannin treatment, this was not
observed at the higher concentration. These results indicate that the PI3K pathway is not
required for migration to the PLN under resting or immunized conditions.
Figures 6 and 7 show that ZAP70 and PI3K signaling are not required for migration of
CD4+ or CD8+ T cells to the PLN during an immune response. Although there was no significant
effect on the total number of CD4+ or CD8+ T cells migrating to the PLN, the inhibition of ZAP70
or PI3K pathways could cause improper localization of treated T cells in the PLN or spleen. To
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examine this possibility, immunofluorescence microscopy of sectioned lymphoid tissues
following adoptive transfer of inhibitor-treated cells was used.
Cells were labeled, treated, and injected as described for Figures 4-7, but the PLN and
spleen were frozen, sectioned, and examined by immunofluorescence microscopy instead of
flow cytometry. Figure 8A shows a representative image of labeled transferred cells in a T cell
zone of the spleen. The image is of piceatannol-treated cells in the spleen but transfer of
wortmannin-treated cells produced similar images. T cell zones were identified based on CD4 or
CD8 antibody labeling and outlined using MetaVue software. Biotin+ and CFSE+ cells were
counted as “In” if they were inside the outlined area and counted as “Out” if they were outside
of the area. The In and Out counts were used to calculate the In/Out ratio for each treatment
and cell type. Figures 8B and 8C show that neither wortmannin nor piceatannol prevented CD4+
or CD8+ T cell migration to the splenic T cell zones after 1 hour of migration. Interestingly, both
the CD4+ and CD8+ wortmannin-treated T cells did have higher In/Out ratios compared to
corresponding control cells in the single experiment.
In another set of experiments, the effects of piceatannol treatment on T cell migration
to and within the PLN were examined. Piceatannol treatment of cells and 1-hour adoptive
transfer was performed as above. The control and immunized PLN were harvested and
sectioned as described. MECA-79 culture supernatant was used to label the HEV, anti-CD4 or
CD8 antibodies were used to visualize the T cell subtypes, and avidin-biotin or CFSE labeling was
used to label the treated (CFSE+) or untreated (biotin+) cells. Figures 9A and 9B show that CD4+
or CD8+ T cells treated with piceatannol exited the HEV and migrated similarly to untreated
CD4+ or CD8+ T cells. This was determined by observing that the treated, transferred CD4+ or
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CD8+ T cells were not contained in the HEV, and that they localized to similar areas as the
untreated T cells did in the PLN. Comparison of the immunized PLN images (Figures 9A and 9B)
to the control PLN (images not shown) showed that the CD4+ and CD8+ T cells exited the HEV
and localized comparably to the control PLN. In summary, wortmannin or piceatannol
treatment of the cells did not affect the localization of CD4+ or CD8+ T cells within the PLNs or
spleen. We next assayed for differences in CD4+ and CD8+ T cell transmigration across the HEV
during short-term migration to determine whether this could account for the observed
differential migration.
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Figure 8. Neither wortmannin nor piceatannol treatment significantly affected the localization of CD4 +
or CD8+ T cells to the T cell zone in the spleen. A) Representative image of a splenic T cell zone from a
piceatannol treatment experiment. Single color images were overlaid to create the final image (bottomright) used to calculate In/Out ratios (Blue=CD8+ T cells, Green= CFSE+ cells (treated), Red= biotin+ cells
(untreated)). Thin arrows indicate the presence of transferred biotin+ cells, and thick arrows indicate
transferred CFSE+ cells. Yellow circle indicates what was considered the T cell zone. Scale bar represents
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50 μm. B) In/Out Ratio of wortmannin treated and untreated CD4+ or CD8+ T cells. C) In/Out Ratio of
piceatannol treated or untreated CD4+ or CD8+ T cells. Results are from 1 experiment.
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Figure 9. Piceatannol treatment did not significantly affect the localization of CD4+ or CD8+ T cells in
the PLN. A) Representative image of CD4+ T cells in an immunized PLN after piceatannol-treated cells
were allowed to migrate for 1 hour. B) Representative image of CD8+ T cells in an immunized PLN after
piceatannol-treated cells were allowed to migrate for 1 hour (Blue=HEV, Green=CFSE+ cells (treated),
Red= Biotin+ cells (untreated), Yellow=CD4+ or CD8+ cells for A and B, respectively). Thin arrows indicate
the presence of transferred subtype+ and biotin+ cells, and thick arrows indicate transferred subtype+
and CFSE+ cells. Scale bar represents 50 μm. Results are from 1 experiment.

Results of previous experiments suggested that T cells were transmigrating across the
HEV faster in immunized PLN than T cells in the control PLN (Grailer, 2010). Therefore, a shortterm adoptive transfer assay was performed to further examine this possibility. Cells were
biotinylated, adoptively transferred into recipient mice immunized 3 days prior and allowed to
migrate for 5 minutes instead of 1 hour after transfer. A representative image of the 5-minute
transfer is shown in Figure 10A. As seen in the image, the labeling was very clean and specific
allowing for easy quantification of the number of transferred cells located inside versus outside
of the HEV. Figure 10B shows the number of biotin+ cells per 1,000 µm2 area of HEV. As
expected for such a short migration time, the majority of the transferred cells were located
inside of the HEV. Furthermore, in this experiment there was no increase in the number of
transferred cells located outside of the HEV in the immunized lymph nodes compared to the
control tissues. Therefore, these initial results do not support the idea that CD4+ or CD8+ T cells
cross the HEV into the PLN faster during an immune response.
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Figure 10. CD4+ or CD8+ T cells do not cross the HEV faster in immunized PLN. A) Representative image
of labeling in lymph node after adoptively transferred cells were allowed to migrate for 5 minutes; Blue=
CD4+ cells; Red= HEV; Green= biotin+ cells. Arrows indicate biotin+ transferred cells within the HEV. All
HEV within a tissue section were scored for biotin+ cells. Scale bar represents 50 μm. B) Graph of biotin+
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cells per 1000 μm2 of HEV in the immunized or control sections. Results are pooled from two sections
made from one transfer experiment.

Discussion
Overall my work found that the differential migration of CD4+ and CD8+ T cells to
immunized peripheral lymph nodes was not dependent on ZAP70 or PI3K signaling. In addition,
ZAP70 and PI3K were not required for proper localization in the PLN or spleen. CD4+ and CD8+ T
cell migration to the immunized lymph nodes was shown to be dependent on Gαi signaling
similarly to the control lymph nodes. It was also shown that CD4+ or CD8+ T cells do not cross
the HEV faster in immunized lymph nodes.
Piceatannol treatment of splenic cells significantly reduced CD8+ T cell migration to the
spleen for mice that were allowed to respond to immunization for 3 and 7 days. This could be
due to the piceatannol reducing the signaling downstream of the T cell receptor (TCR).
Piceatannol has been shown to downregulate p-Erk, p-Akt, and p-p38 specifically (Kim et al.,
2015). Akt is well known to be involved in intracellular signaling pathways that affect adhesion
molecules and receptors involved in lymphocyte migration (Knieke et al., 2012; Stombolic and
Woodgett, 2006). Akt is also known to phosphorylate proteins involved in cell polarization
during migration (Enomoto et al., 2005). It is possible that piceatannol treatment of the cells
affected their shape or deformability, which resulted in changes in circulation rates. However,
this would not explain why CD4+ T cell migration to the spleen was not reduced because the
proteins mentioned are present in both cell types. Further, it is possible that the reduction in
CD8+ T cells found in the spleen was because they had increased migration to tissues not
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sampled such as the lungs, liver, or mucosal lymphoid tissues. Future work could examine the
amount of CD8+ T cells found in these tissues after piceatannol treatment and transfer.
Further, piceatannol’s effect on localization of CD4+ and CD8+ T cells in the PLN and
spleen were examined. Figures 8A, C, and 9A show that piceatannol treatment did not have a
significant effect on the localization of CD4+ or CD8+ T cells. The quantitation of the ratio of cells
In/Out of the splenic T cell zones showed that, although there was a slight increase in the
In/Out ratio of both CD4+ and CD8+ T cells, there would likely not be a significant difference
between the treated and untreated cells with more independent experiments done. Figures 9AB show that there was not a large effect on the localization of piceatannol-treated cells in the
PLN. This was determined by observing that there were no treated cells ‘trapped’ in the HEV of
the PLN, and that the treated and untreated cells localized to similar areas once outside of the
HEV. Quantifying the above observation in the similar ways as Figures 8A-C is complicated by
the fact that there were no cells observed in the HEV after the 1-hour migration. However, it
would be necessary to confirm the observations detailed above with quantitation of 3
independent experiments.
Piceatannol treatment has been found to reduce activation marker expression in
activated CD8+ T cells (Kim et al., 2015). It has also been shown to reduce the transmigration of
CD4+ T cells into resting lymph nodes in 30 minute migration experiments and block the Lselectin-mediated increase in T cell chemotaxis to CCL21 (Subramanian et al., 2012). In the
present studies, the migration of lymphocytes to the PLN, either control or immunized,
following 1 hour of migration was not significantly affected by piceatannol treatment. These
pieces of data, along with Figure 8A, C, and 9A, suggest that ZAP70 does not play a major role in
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the differential migration of CD4+ and CD8+ T cells during an immune response. Some groups
have found that ZAP70 plays a role in the directionality of T cell migration to chemokines in
vitro (Lin et al., 2010). It is possible that the T cells are able to compensate for the loss of ZAP70
signaling, and thus its role in integrin signaling, through synergy in the signaling pathways that
are stimulated by multiple different chemokines engaging the cell at the same time. This
cytokine ‘milieu’ could allow other pathways to compensate for the loss of one signal due to
piceatannol inhibition. Indeed, there are reports of different intracellular pathways being
activated depending on the chemokines, proteins, and T cell subtypes present (Schaeuble et al.,
2011). Also, several reports of synergy between, or among, various chemokine/receptor
networks have been reported (although the exact mechanism of such interaction networks has
been hard to disentangle) (Gouwy et al., 2011; Kuscher et al., 2009). The variables of
chemokine, chemokine receptor, cell type, and cell expression are a few of the parameters of
the cell migration formula. Although nascent, the development of high-throughput methods for
characterization of signaling pathway synergy with various perturbations has begun to unwind
complex networks such as chemokine signaling (Bendall et al., 2011). It would be interesting to
look for a possible synergy among pathways in piceatannol-treated cells, which allowed the
cells to compensate for loss of ZAP70 signaling by using a high-throughput method (e.x. singlecell mass cytometry).
Previous studies using in vitro transwell migration assays had shown that wortmannin
treatment of cells does reduce migration to CCL21 (Subramanian, 2012). Given PI3K’s
importance in signaling, it is surprising that wortmannin inhibition of PI3K did not affect CD4+ or
CD8+ T migration to the peripheral lymph nodes as shown in Figures 7A-B. Further,
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quantification of spleen sections with wortmannin-treated or untreated cells (Figure 8B)
showed that wortmannin treatment did not influence the localization of CD4 + or CD8+ T cells to
splenic T cell areas. It is likely that wortmannin treatment of CD4+ and CD8+ T cells would not
have a significant effect on localization in the PLN, although this was not examined. Some
previous reports using wortmannin to inhibit PI3K proteins support this result (Matheu et al.,
2007, Asperti-Boursin et al., 2007). As with Figure 6, the discrepancy could be explained by
crosstalk compensation of the various signaling pathways and chemokines. It is possible that
the cells can incorporate various other chemokine signaling and/or pathways to allow them to
make up for the loss of pan-PI3K signaling due to wortmannin treatment. Importantly, ApspertiBoursin and others found that cells treated with wortmannin at 100nM maintained PI3K
inhibition for at least 2 hours. This adds support to the data in Figure 7 in lieu of western blot
data of my own. Overall, these results support the idea that the mechanism for regulating the
differential migration of CD4+ and CD8+ T cells during an immune response is not wholly
dependent on ZAP70 and PI3K signaling.
Finally, results shown in Figure 10 suggest that CD4+ and CD8+ T cells do not cross the
HEV significantly faster in immunized compared to control peripheral lymph nodes using 5minute migration assays. However, it is possible that a 5-minute migration assay is simply too
short for migration out of the HEV to occur in either tissue. A difference in migration between
the resting and immunized PLN might be found if the cells were given a little more time to
migrate across the HEV. A similar assay with a 10-minute migration time could address this
question.
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Future Directions and Conclusion
Follow up transfer assays with immunofluorescence microscopy should be done to
quantitate the results qualitatively shown in Figure 9A-B. Although initial images from the first
experiment suggest there is no difference in migration with piceatannol treatment at this time
point, this should be confirmed. Interestingly, in Figure 9A-B there seemed to be fewer treated
cells in the control peripheral lymph node images (CFSE+ cells) compared to the immunized PLN.
This result is not consistent with the data in Figure 6 that showed there was no reduction of
CD4+ or CD8+ T cell migration to the control peripheral lymph node with piceatannol treatment.
It is possible that the lack of CFSE+ cells in the control peripheral lymph node was an artifact of
the sectioning or labeling of the tissue. Labeling more sections from the same control
peripheral lymph node tissue could confirm the result. Also, transfer and immunofluorescence
imaging with wortmannin-treated cells would be a good follow up on Figure 9A-B.
The majority of groups that study T cell migration examine chemokine signaling as a
large aspect of the migration ‘equation’. It would be interesting to examine the dynamics of the
cytokine ‘milieu’ and how it is affected by the immunization procedure used in our studies.
Using a high-throughput Liquid Chromatography-Mass Spectroscopy approach could provide
data that would tell us what chemokines are expressed differently in immunized mice
compared to the unimmunized mice.
Opposite of chemokine expression are the cells that are sensing and responding to
them. Examination of CD4+ and CD8+ T cell gene expression and/or transcriptome could
elucidate some differences in intracellular responses to cytokine exposure that might help
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explain the differential migration. Indeed, some groups have used high-throughput, ‘systems’
methods to examine the intracellular signaling that takes place before cell activation (Hat et al.,
2011, Bordbar et al., 2012, De Simone et al., 2016). Multicolor fluorescence associated cell
sorting with rtPCR on the single-cell populations would be a good method to look at expression
of chemokine receptors and/or gene expression in response to chemokine exposure. Those
methods in conjunction could hint at which chemokine signaling pathways to focus on with
inhibitors or gene knockouts to tease apart the differential migration.
The data shown and discussed in this work, although not conclusive, has eliminated
possibilities for the observed differential migration of CD4+ and CD8+ T cells during an immune
response and suggested new possibilities. A better understanding of the migration mechanisms
used by T cells could allow design of T cells with improved migration to tumor sites, as has been
a noted issue for some immunotherapeutic regimens (Sackstein et al., 2017). This knowledge
could also add to the development of immunotherapies for autoimmune diseases (Pozsgay et
al., 2017). In all, this work adds to the ever-growing knowledge of T cell migration and, in the
future, will hopefully be useful for therapies that help patients’ lives.
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Appendix
Introduction
Deacetylation of histones by histone deacetylases (HDACs) has been implicated in
regulation of gene expression for many years (Allfrey et al., 1964). The biochemical pathways
and wider effects on gene regulation of HDACs have been uncovered since these initial studies
in the 1960s (Seto and Yoshida, 2014). The role of HDACs in gene regulation has become even
more appreciated with the advent of epigenetic studies in recent years. HDACs role(s) in cancer
garnered interest from groups once more information became available about its role in gene
regulation. HDAC inhibitors (HDACi) have been studied clinically because of this interest (West
and Johnstone, 2014). There are four FDA-approved HDACi as of 2018 (Vorinostat™,
Romidepsin™, Panobinostat™, Belinostat™) with strong interest in developing new HDACi as
evidenced by the 608 on-going or completed clinical studies investigating HDACi (Hervouet,
2018; Clinicaltrials.gov). However, a lack of specificity, and intolerable levels of toxicity, has
limited the development of HDACi outside of the currently approved inhibitors.
Toxicity issues with current HDACi and continued interest in the development of HDACi
for cancer lead to the collaboration between the Hossain lab and Steeber lab. The Hossain lab
had previously synthesized novel HDACi based on the chemical structure of Romidepsin™
(FK228). The modifications made by the Hossain group were designed to reduce the toxicity of
the new HDACi by increasing their class specificity. The Hossain group had synthesized 12
structural variants, including addition of different functional groups, and termed the variants
compound 1-6 (Cpd1-6) and Cpd1-6’. The Hossain group delivered batches of the purified
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compounds to the Steeber lab for testing of the drugs in vitro as described below. The data
from the assays performed show that one of the compounds (Cpd1’) reduced prostate cancer
(DU145 cells) viability and inhibited HDAC activity in vitro.
MTT assay
Cells were allowed to adhere for 24 hours at 37°C with 5% CO2. Compound 1’ (Cpd1’),
Compound 5 (Cpd5), FK228, and DMSO control concentrations were diluted in series with
supplemented DMEM. The media was aspirated off the 96 well plate and the drug, or control,
concentrations were added to the plate in triplicate. The cells were incubated with the drugs or
DMSO controls for 48 hours. The drug and control treatments were removed and 200 µg/mL 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Research Products
International, Mount Prospect, IL) diluted in supplemented DMEM was added to each well.
Cells were incubated with the MTT for 4 hours at 37°C with 5% CO2. The MTT solution was
aspirated off and 200 µL DMSO was added to each well. The plate was mixed on a rotator for 10
minutes at a moderate pace and then the wells were mixed with a pipettor to dissolve all the
MTT in each well. The plate was read at 570 nm with the reference wavelength at 690 nm on a
Molecular Devices Versamax plate reader (San Jose, CA). The reference wavelength absorbance
for each well was subtracted. The average for the triplicate blank wells was calculated and also
subtracted from each well. The % viability of each concentration was calculated by dividing the
average absorbance for each drug concentration by the DMSO control for that concentration
(average drug concentration absorbance/average DMSO control absorbance).
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H3 Acetylation Assay
DU145 cells were cultured as above. Cells were counted and resuspended at 60,000
cells/mL in supplemented DMEM. 1mL of cells at 60,000 cells/mL were added to wells of a 24
well plate. The cells were allowed to adhere for 24 hours at 37°C with 5% CO2. The media was
aspirated and Cpd1’ at 50, 5, or 0.5 μM concentrations, or DMSO controls, in supplemented
DMEM were added to the wells in duplicate. The plate was incubated at 37°C with 5% CO2 for
24 hours. Cells were fixed with 350-500 μL 4% paraformaldehyde for 10 minutes at room
temperature after the 24-hour incubation. 400-500 μL Tris buffered saline with 0.1% Tween 20
and 1% Bovine Serum Albumin (TBS-T w/ 1% BSA) was added to each well for 1 hour at 4°C for
permeabilization. TBST w/ 1% BSA was removed and 350 to 500 μL rabbit anti-acetyl-Histone
H3 (Lys9/Lys14) antibody (Cell Signaling Technology, Danvers, MA) at a 1:2000 dilution in TBS-T
w/1% BSA was added to each well. The primary antibody was incubated with the cells overnight
at 4°C. The primary antibody was removed and goat anti-rabbit IgG AlexaFluor™ 488 (Jackson
ImmunoResearch, West Grove, PA) at a 1:500 dilution was added to each well and incubated
for 1.5 hours at 4°C. The plate was removed from 4°C and 350-500 μL DAPI at 0.3 μg/mL was
added to each well. DAPI was incubated in dark at room temperature for 15 minutes. Finally,
wells were imaged with the fluorescence microscope as described in the main article’s
Materials and Methods section.
Results
Cpd1’ had anti-proliferative activity at 50 uM as shown in Figure 11A. There was a
significant reduction in cellular proliferation at 50 μM compared to 5 μM. However, the activity
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of Cpd1’ did not extend past the 50 μM concentration. A single follow up experiment showed
that Cpd1’ had anti-proliferative effects down to about 20-30 μM concentrations (data not
shown). The histone deacetylase inhibitor (HDACi) activity of Cpd1’ was assayed by
immunofluorescence labeling of the acetylated form of the histone H3 protein. The antibody
labeling detected acetylated lysine 9 and lysine 14 on the H3 protein. Increased fluorescence
would indicate that the compound was not allowing the deacetylation of the H3 protein and
thus indicate HDACi activity for Cpd1’. Figure 11B shows that the 50 μM concentration of Cpd1’
increased the acetylation of the H3 protein compared to the DMSO control in DU145 cells. This
indicates that Cpd1’ has HDACi activity. The increase of acetylation at the 50 μM dose
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correlates with the significant decrease in proliferation at the 50 μM dose shown in Figure 11A.
This suggests that Cpd1’ is reducing cell proliferation via HDACi activity.
Cpd5 was tested with the same MTT procedure and concentrations as Cpd1’. Figure 12
shows that Cpd5 did not have detectable anti-proliferative effects on the DU145 cells as
measured by % viability.
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Figure 11. Cpd1’ significantly reduced DU145 cell viability after treatment for 48 hours and had histone
deacetylase activity after 24 hours. A) DU145 cells were treated and MTT conversion was measured as
above. The % viability was calculated as above. The 50 μM treatment results are from 3 independent
experiments while the 5, 0.5, and 0.05 μM treatment results are from 2 independent experiments. Error
bars indicate SEM. Asterisk above bar indicates significant difference between results at either end of
bar. * p < 0.05 B) Representative images of histone H3 acetylation after treatment with DMSO or Cpd1’.
Blue indicates nuclear staining by DAPI and Green indicates the presence of acetylated H3 histone.

100%

% Viability

80%

60%
40%
20%
0%
50 μM

5 μM
.5 μM
Cpd5 Concentration

.05 μM

Figure 12. Cpd5 did not significantly reduce the % Viability of DU145 cells. The MTT assay was
performed as described above with the concentrations shown. % viability was calculated as above.
Results are from 1 experiment.

Discussion and Future Directions
Previous MTT assays with Cpd5 found that the compound significantly reduced DU145
cell proliferation at nanomolar concentrations. Figure 12 shows that there was no significant
reduction in proliferation by Cpd5 even at the 50 μM concentration. This suggests that the
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compound was not as active as it was in previous experiments. The FK228 positive control
achieved reduction of proliferation in the previously reported nanomolar range (data not
shown), and Cpd1’ showed reduction in the micromolar range. Accordingly, it is not likely that
differences in the MTT assay are to blame. It is possible that the synthesis and/or purification of
the compound was not the same as in previous assays. Cpd5 received from Dr.Hossain’s group
will be tested with the MTT assay as described above until an active batch of the compound is
found. Follow up MTT assays could also be done with Cpd1’ to further define the effective
range for the compound.
Figure 11B qualitatively shows that Cpd1’ had strong HDACi activity at the 50 μM
concentration. Preliminary testing was done on an assay using flow cytometry to quantitate the
level of H3 acetylation. A quantitative measure of H3 acetylation would allow for stronger
support of the conclusion that Cpd1’ had significantly higher HDACi activity than the DMSO
control. It would also further support the correlation between Cpd1’s HDACi activity and antiproliferative effects.
Pharmacokinetic studies of Cpd1’ in mouse model(s) would be the next step in the
consideration of the compound as a cancer therapeutic. Injecting Cpd1’ intraperitoneally (i.p.)
at a yet to be determined concentration (presumably in the mg/kg range) and sampling blood
at 30-minute intervals via a retroorbital eye bleed procedure could be a good start to
understanding the pharmacokinetics of the drug. It would also be interesting to sample various
tissues (e.g. spleen, lymph nodes, kidney, heart, intestine) to examine the distribution of the
drug in the mouse after injection. These tissues could be sampled from control and
experimental mice at 12, 24, and 48 hours after i.p. injection of the drug as a first experiment.
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Finally, a dosing study to examine the effectiveness of Cpd1’ in a mouse tumor model
would be necessary to show effectiveness in vivo. Cpd1’ could be injected i.p. into mice bearing
tumors. Female Balb/c mice bearing 4T1 tumors in their mammary fat pads to model stage IV
breast cancer is a model used in the Steeber lab to examine myeloid-derived suppressor cell
(MDSC) biology in tumors. It would be interesting to see the effects, if any, of Cpd1’ on the
growth of 4T1 tumors. Most 4T1 tumors are visible as a small bump at the injection site 2 weeks
post injection. The pharmacokinetics data from the suggested experiments would be useful to
set up the dosing plan, but an a priori plan could be to dose the mice with Cpd1’ in the mg/kg
range once weekly starting one week after tumor injection. Tumor area could be measured
with calipers, and control versus treated tumors would be compared. It would be possible to
inject the compound and control directly into the tumor if no effect is found with i.p. dosing to
determine if the dosing was not high enough or if the compound is not effective in vivo.
These data shown, and future studies suggested, would provide more information on
the effectiveness of Cpd1’ in vivo. These efforts would hopefully show the compound to be an
effective cancer therapeutic and be a viable option to help patients with the disease.
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